Table1.
Demographic and clinical profiles of PD patients and control groups.
| Controls | PD | Hoehn&Yahr stage I | Hoehn&Yahr stage II | Hoehn&Yahr stage III | p Valuea | |
|---|---|---|---|---|---|---|
| No. of subjects | 80 | 80 | 29 | 25 | 26 | — |
| Age, y | 63.3 ± 5.4 | 64.0 ± 5.8 | 64.2 ± 5.9 | 63.0 ± 6.7 | 64.7 ± 5.0 | 0.777 |
| F/M | 32/48 | 32/48 | 12/17 | 12/13 | 8/18 | 0.807 |
| Disease duration, mo | — | 52.9 ± 52.2 | 23.7 ± 20.0 | 60.8 ± 63.7 | 77.8 ± 50.7d | 0.001 |
| UPDRS (motor)b | — | 27.9 ± 14.0 | 16.6 ± 6.0 | 30.8 ± 9.2d | 37.5 ± 15.6e | < 0.001 |
| Levodopa equivalent dose (mg/day) | — | 312.4 ± 319.2 | 196.7 ± 269.4 | 301.7 ± 300.9 | 451.8 ± 343.4c | 0.030 |
| No. of drug-naïve patients | — | 19 | 10 | 8 | 1 | — |
| MMSE | — | 27.4 ± 2.5 | 28.2 ± 1.4 | 26.9 ± 2.3 | 27.0 ± 3.4 | 0.331 |
Abbreviations: PD = Parkinson disease; UPDRS = Unified Parkinson’s Disease Rating Scale; MMSE = Mini Mental State Examination. The data are presented as mean ± SD.
aAnalysis of variance with the exception of chi-square for gender.
bOff-state motor ratings according to the UPDRS.
cp < 0.05 vs. Hoehn & Yahr stage I group.
dp < 0.01 vs. Hoehn & Yahr stage I group.
ep < 0.001 vs. Hoehn & Yahr stage I group.